Trianglepembrolizumab (NCT03618550)
pembrolizumab trial for Hodgkin Lymphoma (NCT03618550). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with biopsy-confirmed classical Hodgkin lymphoma that returned or resisted first-line chemotherapy, who can undergo stem-cell transplantation.
The idea: pembrolizumab releases immune brakes alongside gemcitabine, vinorelbine and liposomal doxorubicin chemotherapy. Treatment paths differ by study part and response. Some complete responders enter a randomized comparison of autologous transplantation against further combination treatment followed by pembrolizumab maintenance. Radiation is restricted to selected patients.
This phase 2 study plans 257 patients. Alison Moskowitz leads at Memorial Sloan Kettering in New York. Nine US locations are marked recruiting; one is data-only.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.